Corporate Philosophy Unleashing SLC Transporters Against Incurable Disease

We define our Corporate Philosophy as: “By pursuing new possibilities for SLC transporters and developing innovative new drugs that address unmet medical needs, we will contribute to supporting people around the world to maintain good health and hope.”


Our focus lies in the development of L-type amino acid transporter 1 (LAT1), an essential amino acid transporter discovered by J-Pharma’s founder. We are developing LAT1 inhibitors that have the potential to address unmet medical needs for the treatment of cancers and autoimmune disorders, especially for patients who are not covered by available treatment options. We have two LAT1 inhibitors in our development pipeline: nanvuranlat (target indication: biliary tract cancer, potential indication expansion: colorectal cancer, renal cell carcinoma) and JPH034 (target indication: secondary progressive multiple sclerosis, brain tumors). We have also identified promising hit compounds among LAT1 inhibitors and other SLC transporter inhibitors, with further development currently underway.

We have established a global development structure and founded a U.S. subsidiary in October 2023. We are working closely with its members and U.S. consultants to develop appropriate regulatory, development, and intellectual property rights strategies.

Nanvuranlat has demonstrated long-term safety and tolerability (refer “Pipeline” for details), positioning it as a potential treatment option for numerous biliary tract cancer patients globally, especially those with limited existing therapies. Upon receiving regulatory approval, our strategy involves marketing the drug globally by appropriately selecting in-house marketing and out-licensing for each region.

We aim to continuously expand as a global drug discovery venture by leveraging our robust SLC transporter platform and global regulatory and clinical development infrastructure.